https://www.selleckchem.com/pr....oducts/ca-074-methyl
0937). HRs for participants aged less then 65, 65 to less then 75 and ≥75 years were 1.11 (95% CI 0.89, 1.4, 1.09 (0.89, 1.33) and 0.76 (0.57, 1.02), respectively. Linagliptin did not increase the risk of adverse kidney outcomes or hospitalization for heart failure across age groups. The incidence of adverse events, including hypoglycaemia, increased with age but was similar with linagliptin and placebo despite glycated haemoglobin A1c reduction with linagliptin. CONCLUSIONS Linagliptin did not increase risk for cardiovasc